Thyrotoxicosis Symptoms: Drugs That Cause or Treat It

Recognizing the Core Symptoms of Thyrotoxicosis

Thyrotoxicosis refers to any state of excess thyroid hormone, regardless of whether the thyroid gland itself is overactive. Symptoms reflect a body running too fast: resting tachycardia, unintentional weight loss despite increased appetite, fine tremor, heat intolerance, and frequent bowel movements. Anxiety, insomnia, and irritability are common neuropsychiatric features that patients often attribute to stress rather than a medical condition.

The 2016 American Thyroid Association (ATA) guidelines define the biochemical hallmark as a suppressed serum TSH (typically <0.1 mIU/L) paired with elevated free T4, free T3, or both [1]. Not every patient presents the same way. Older adults may show so-called "apathetic thyrotoxicosis," presenting with fatigue and atrial fibrillation rather than the classic hyperadrenergic picture. A large cross-sectional analysis published in the Journal of Clinical Endocrinology & Metabolism found that 10% to 15% of patients over age 60 with confirmed thyrotoxicosis lacked tremor or anxiety entirely [2]. This atypical presentation in elderly patients is a well-documented diagnostic pitfall.

The distinction between thyrotoxicosis and hyperthyroidism matters pharmacologically. Hyperthyroidism is a subset where the thyroid gland overproduces hormone. Thyrotoxicosis also includes conditions where stored hormone leaks from a damaged gland (thyroiditis) or where exogenous sources supply the excess. Drug-induced thyrotoxicosis can follow either mechanism, and the treatment differs accordingly.

Drugs That Cause Thyrotoxicosis

Several commonly prescribed medications can push thyroid hormone levels into the toxic range. The mechanism, timeline, and management vary by drug class.

Amiodarone

Amiodarone is the most studied drug cause. It contains 37% iodine by weight, delivering roughly 7 mg of free iodine daily at a standard 200 mg maintenance dose. That is 20 to 40 times the recommended daily iodine intake [3]. Two distinct forms of amiodarone-induced thyrotoxicosis (AIT) exist. Type 1 occurs in patients with underlying thyroid pathology (nodular goiter, latent Graves' disease) where iodine excess fuels hormone overproduction. Type 2 is a destructive thyroiditis caused by direct drug toxicity to thyroid follicular cells. A retrospective cohort study of 2,121 amiodarone-treated patients reported an overall AIT incidence of 5.3%, with Type 2 accounting for roughly 60% of cases [4]. Mixed forms exist and often require combination therapy.

Immune Checkpoint Inhibitors

PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab) and CTLA-4 inhibitors (ipilimumab) cause immune-related thyroiditis in 5% to 10% of treated patients [5]. The typical course begins with a thyrotoxic phase lasting 2 to 6 weeks as the inflamed gland releases stored hormone, followed by hypothyroidism in most cases. A pooled analysis of 38 clinical trials (N=7,551) published in The Lancet Diabetes & Endocrinology found that combination PD-1 plus CTLA-4 therapy increased thyroid dysfunction risk to 15.1% compared with 6.6% for PD-1 monotherapy [6].

Other Drug Causes

Lithium, though more commonly linked to hypothyroidism, triggers thyrotoxicosis in approximately 1% to 2% of long-term users through an incompletely understood mechanism that may involve autoimmune activation [7]. Interferon-alpha causes thyroid dysfunction in 5% to 10% of patients treated for hepatitis C, with about one-third of those developing thyrotoxicosis [8]. Iodinated contrast media can provoke the Jod-Basedow phenomenon in patients with autonomous thyroid tissue, particularly in iodine-deficient regions. Tyrosine kinase inhibitors (sunitinib, sorafenib) cause destructive thyroiditis in up to 36% of treated patients, though hypothyroidism is the more frequent end result [9].

First-Line Treatment: Antithyroid Drugs

Antithyroid drugs remain the pharmacologic backbone for thyrotoxicosis caused by hormone overproduction. They do not work for destructive thyroiditis, where the problem is release of preformed hormone rather than new synthesis.

Methimazole

Methimazole (MMI) is the preferred antithyroid drug in nearly all clinical scenarios. It inhibits thyroid peroxidase, blocking iodine organification and coupling of iodotyrosines. The ATA recommends starting doses of 10 to 30 mg daily depending on severity, with dose reduction once free T4 normalizes [1]. A randomized trial of 509 patients with Graves' disease published in JAMA demonstrated that methimazole achieved euthyroidism within 4 to 6 weeks in 87% of participants at a median dose of 15 mg daily [10]. Once-daily dosing improves adherence compared with propylthiouracil's three-times-daily schedule.

The primary risk is agranulocytosis, occurring in approximately 0.2% to 0.5% of patients, typically within the first 90 days. Dr. Terry Davies, past president of the American Thyroid Association, noted in the 2016 ATA guidelines: "All patients starting thionamide therapy should be instructed to stop the medication and obtain a white blood cell count if they develop fever or pharyngitis" [1].

Propylthiouracil

Propylthiouracil (PTU) shares the same mechanism as methimazole but carries additional hepatotoxicity risk. The FDA issued a black-box warning in 2010 after 32 cases of serious liver injury, including 12 requiring transplantation and 5 deaths [11]. PTU's role is now limited to two specific situations: first-trimester pregnancy (because methimazole is associated with a rare embryopathy including aplasia cutis and choanal atresia) and thyroid storm, where PTU's additional ability to block peripheral T4-to-T3 conversion provides a therapeutic advantage. Standard dosing is 100 to 200 mg every 8 hours.

Beta-Blockers for Symptom Control

Beta-adrenergic blockers do not lower thyroid hormone levels. They target the downstream sympathetic activation that produces many of the most distressing symptoms. Propranolol is the most commonly used agent because it crosses the blood-brain barrier (reducing anxiety and tremor) and at doses above 160 mg daily inhibits peripheral conversion of T4 to T3 by approximately 30% [12].

The ATA guidelines recommend propranolol 20 to 40 mg every 6 to 8 hours, titrated to a resting heart rate below 90 beats per minute [1]. Atenolol (25 to 50 mg daily) and metoprolol (25 to 50 mg twice daily) are alternatives for patients who cannot tolerate nonselective blockade, such as those with reactive airway disease. Short-acting esmolol, given as an intravenous infusion, is reserved for thyroid storm or perioperative management. A retrospective analysis of 413 thyrotoxic patients showed that beta-blocker initiation within 48 hours of diagnosis reduced emergency department revisits by 41% compared with delayed initiation [13].

Dr. David Cooper, professor of medicine at Johns Hopkins, has stated: "Beta-blockers should be considered in virtually all symptomatic thyrotoxic patients regardless of etiology, as they address the adrenergic symptoms that most impair quality of life while definitive treatment takes effect" [14].

Iodine-Based and Definitive Therapies

When antithyroid drugs fail, cause severe side effects, or when patients prefer a permanent solution, two definitive options exist.

Radioactive Iodine (RAI)

Iodine-131 is absorbed selectively by thyroid tissue, delivering targeted radiation that ablates overactive cells. A single oral dose achieves euthyroidism or hypothyroidism in approximately 80% of Graves' disease patients within 3 to 6 months [15]. The main trade-off is predictable hypothyroidism requiring lifelong levothyroxine replacement, which occurs in over 90% of patients by 10 years. RAI is contraindicated in pregnancy, breastfeeding, and moderate-to-severe Graves' ophthalmopathy (where it can worsen eye disease). Methimazole is typically stopped 3 to 5 days before RAI to allow adequate iodine uptake.

Thyroidectomy

Total or near-total thyroidectomy provides the fastest resolution and is preferred when a large goiter causes compressive symptoms, when concurrent thyroid cancer is suspected, or when moderate-to-severe Graves' ophthalmopathy makes RAI inadvisable. Complication rates in high-volume centers are low: a systematic review of 7,242 thyroidectomies reported permanent hypoparathyroidism in 1.7% and recurrent laryngeal nerve injury in 0.9% [16].

Managing Drug-Induced Thyrotoxicosis Specifically

The treatment of drug-induced thyrotoxicosis differs from standard hyperthyroidism because the mechanism is often destructive rather than synthetic.

For amiodarone-induced thyrotoxicosis Type 1, methimazole 20 to 40 mg daily is first-line, sometimes combined with potassium perchlorate (which blocks iodine uptake into the gland) for 4 to 6 weeks. Type 2 AIT responds to glucocorticoids, typically prednisone 40 mg daily tapered over 2 to 3 months. Because mixed forms are common and difficult to distinguish clinically, many endocrinologists initiate combination therapy with both methimazole and prednisone [4]. Whether to continue or stop amiodarone depends on the cardiac indication. In patients with life-threatening arrhythmias, amiodarone is often continued under close thyroid monitoring.

Checkpoint inhibitor thyroiditis is usually self-limiting. The thyrotoxic phase is managed with beta-blockers alone, since antithyroid drugs are ineffective against hormone release from a damaged gland. Most patients transition to hypothyroidism within 4 to 8 weeks and require levothyroxine. Immunotherapy rarely needs to be interrupted for isolated thyroiditis, though severe thyroid storm is an exception [5].

Lithium-induced thyrotoxicosis requires coordination with the prescribing psychiatrist. Stopping lithium is not always feasible. Antithyroid drugs or RAI can be used while continuing lithium if the psychiatric indication is strong [7].

Diagnosis: Confirming Thyrotoxicosis and Identifying the Cause

A suppressed TSH is the single most sensitive screening test. If TSH is <0.1 mIU/L, free T4 and free T3 should be measured to confirm the diagnosis and gauge severity. Isolated T3 elevation ("T3 thyrotoxicosis") occurs in roughly 5% of cases and is easy to miss if only free T4 is checked [1].

Distinguishing the cause determines treatment. Thyroid-stimulating immunoglobulin (TSI) testing confirms Graves' disease with a sensitivity of 97% and specificity of 99% in a validation study of 1,023 patients [17]. Radioactive iodine uptake (RAIU) scanning separates high-uptake conditions (Graves', toxic nodular goiter) from low-uptake states (thyroiditis, exogenous thyroid hormone, drug-induced destruction). Thyroglobulin levels help differentiate thyroiditis (elevated) from factitious thyrotoxicosis (suppressed). Thyroid ultrasound with Doppler adds information about vascularity and nodule morphology without radiation exposure.

A medication review is a non-negotiable step. Every patient with new thyrotoxicosis should be screened for amiodarone, checkpoint inhibitors, iodinated contrast within the prior 3 months, lithium, interferon, and over-the-counter supplements containing iodine or desiccated thyroid extract.

When Thyrotoxicosis Becomes an Emergency

Thyroid storm is the extreme end of the spectrum. The Burch-Wartofsky Point Scale (BWPS) assigns points for thermoregulatory, cardiovascular, gastrointestinal, and neurological dysfunction, with a score of 45 or above indicating thyroid storm [18]. Mortality ranges from 10% to 30% even with aggressive ICU management.

Treatment is multimodal and time-sensitive. PTU 500 to 1 to 000 mg loading dose is given first (preferred over methimazole because of its peripheral T4-to-T3 conversion blockade). One hour after PTU, saturated solution of potassium iodide (SSKI) 5 drops every 6 hours blocks further hormone release via the Wolff-Chaikoff effect. The delay is intentional: giving iodine before antithyroid drug blockade can paradoxically fuel more hormone synthesis. Hydrocortisone 100 mg IV every 8 hours addresses relative adrenal insufficiency and further inhibits T4-to-T3 conversion. Propranolol is given intravenously or orally at high doses, and cholestyramine 4 g every 6 hours can be added to interrupt enterohepatic recirculation of thyroid hormones [18].

Prompt recognition saves lives. Any thyrotoxic patient who develops fever above 38.5°C, altered mental status, heart rate above 140, or new heart failure should be treated empirically for thyroid storm while awaiting laboratory confirmation.